Journal Mobile Options
Table of Contents
Vol. 65, No. 4, 2003
Issue release date: July–August 2003
ORL 2003;65:219–222

Natural Killer Cell Lymphoma of the Parotid Gland

Furukawa M. · Suzuki H. · Tohmiya Y. · Matsuura K. · Takahashi E. · Ichinohasama R. · Kobayashi T.
Departments of aOtorhinolaryngology and bInternal Medicine, Sendai National Hospital, cDepartment of Otorhinolaryngology, Head and Neck Surgery and dDepartment of Oral Pathology, Tohoku University, School of Dentistry, Sendai, Japan

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


The majority of all parotid lymphomas are of the non-Hodgkin type and of B-cell origin. Primary natural killer cell lymphomas of the parotid gland are extremely rare. We present a case of natural killer cell lymphoma in a 34-year-old woman. The disease was refractory to chemotherapy, and the patient eventually succumbed due to lymphoma-associated hemophagocytic syndrome.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Jaffe ES: Lymphoid lesions of the head and neck: A model of lymphocyte homing and lymphomagenesis. Mod Pathol 2002;15:255–263.
  2. Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR, Costa J, Decker JL, Chused TM: Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978;89:888–892.
  3. Arber DA, Weiss LM, Albujar PF, Chen YY, Jaffe ES: Nasal lymphomas in Peru: High incidence of T-cell immunophenotype and Epstein-Barr virus infection. Am J Surg Pathol 1993;17:392–399.
  4. Elenitoba-Johnson KS, Zarate-Osorno A, Meneses A, Krenacs L, Kingma DW, Raffeld M, Jaffe ES: Cytotoxic granular protein expression, Epstein-Barr virus strain type, and latent membrane protein-1 oncogene deletions in nasal T-lymphocyte/natural killer cell lymphomas from Mexico. Mod Pathol 1998;11:754–761.
  5. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, et al: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994;84:1361–1392.
  6. Jaffe ES, Chan JK, Su IJ, Frizzera G, Mori S, Feller AC, Ho FC: Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell Lymphomas: Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 1996;20:103–111.
  7. Chiang AK, Chan AC, Srivastava G, Ho FC: Nasal T/natural killer (NK)-cell lymphomas are derived from Epstein-Barr virus-infected cytotoxic lymphocytes of both NK- and T-cell lineage. Int J Cancer 1997;4;73:332–338.
  8. Nasuti JF, Yu G, Boudousquie A, Gupta P: Diagnostic value of lymph node fine needle aspiration cytology: An institutional experience of 387 cases observed over a 5-year period. Cytopathology 2000;11:18–31.
  9. Loo CK, Quach HT, Gallo J: Diagnosis of natural killer cell lymphoma by cytology and flow cytometric immunophenotyping: A case report. Acta Cytol 2002;46:877–882.
  10. Chan JK, Tsang WY, Hui PK, Ng CS, Sin VC, Khan SM, Siu LL: T- and T/natural killer-cell lymphomas of the salivary gland: A clinicopathologic, immunohistochemical and molecular study of six cases. Hum Pathol 1997;28:238–245.
  11. Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, LeBlanc M, Carlin S, Chase E, Fisher RI: Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med 1998;2;339:21–26.
  12. Drenou B, Lamy T, Amiot L, Fardel O, Caulet-Maugendre S, Sasportes M, Diebold J, Le Prise PY, Fauchet R: CD3– CD56+ non-Hodgkin’s lymphomas with an aggressive behavior related to multidrug resistance. Blood 1997;15;89:2966–2974.
  13. Takahashi N, Miura I, Chubachi A, Miura AB, Nakamura S: A clinicopathological study of 20 patients with T/natural killer (NK)-cell lymphoma-associated hemophagocytic syndrome with special reference to nasal and nasal-type NK/T-cell lymphoma. Int J Hematol 2001;74:303–308.
  14. Nagata H, Konno A, Kimura N, Zhang Y, Kimura M, Demachi A, Sekine T, Yamamoto K, Shimizu N: Characterization of novel natural killer (NK)-cell and gammadelta T-cell lines established from primary lesions of nasal T/NK-cell lymphomas associated with the Epstein-Barr virus. Blood 2001;97:708–713.

Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00